ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director William W. Wyman received two option awards to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, expiring on May 20, 2036. A second grant covers 5,500 options on the same terms.

According to the footnotes, one grant vests in full on May 20, 2027, while another vests with 25% upon grant and the remainder ratably over thirty-six months, in each case subject to continued service on the Board.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider WYMAN WILLIAM W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	5,500	$0.00	--
Grant/Award	Option (right to buy)	11,000	$0.00	--

Holdings After Transaction: Option (right to buy) — 5,500 shares (Direct, null)

Footnotes (1)

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

Key Figures

Option grant 1 size: 11,000 options Option grant 2 size: 5,500 options Exercise price: $10.77 per share +4 more

7 metrics

Option grant 1 size 11,000 options Derivatives awarded to buy Common Shares

Option grant 2 size 5,500 options Additional derivatives awarded to buy Common Shares

Exercise price $10.77 per share Conversion or exercise price for both option grants

Expiration date May 20, 2036 Expiration for both option awards

Vesting date (full vest grant) May 20, 2027 One option grant vests in full on this date

Immediate vesting portion 25% of shares Of one grant, vests upon grant

Ratable vesting period 36 months Remaining shares of one grant vest ratably

Key Terms

Option (right to buy), conversion or exercise price, expiration date, vest, +1 more

5 terms

Option (right to buy) financial

"security_title: Option (right to buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 10.7700"

expiration date financial

"expiration_date: 2036-05-20T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest financial

"The shares subject to this option shall vest in full on May 20, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

ratably over thirty-six months financial

"remaining shares vesting ratably over thirty-six months"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WYMAN WILLIAM W

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		5,500		(1)	05/20/2036	Common Shares	5,500	$0	5,500	D
Option (right to buy)	$10.77	05/20/2026		A		11,000		(2)	05/20/2036	Common Shares	11,000	$0	11,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

	/s/ Max Milbury, Attorney in Fact for William Wyman	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for William W. Wyman?

ProMIS Neurosciences reported that director William W. Wyman received two option awards. He was granted 11,000 options and 5,500 options to buy Common Shares, both with a $10.77 exercise price and an expiration date of May 20, 2036.

What are the exercise terms of the new PMN stock options granted to William Wyman?

The options granted to William Wyman allow him to buy ProMIS Neurosciences Common Shares at $10.77 per share. Both the 11,000-option and 5,500-option grants share this exercise price and have an expiration date of May 20, 2036, if not exercised earlier.

How do the vesting schedules work for William Wyman’s new ProMIS Neurosciences options?

One option grant to William Wyman vests in full on May 20, 2027, contingent on continued Board service. Another grant vests 25% immediately upon grant, with the remaining shares vesting ratably over thirty-six months, also subject to continued Board service throughout the vesting period.

Is William W. Wyman buying or selling ProMIS Neurosciences stock in this Form 4?

This Form 4 shows option grants to William W. Wyman rather than market purchases or sales. Both transactions are classified as awards (code A), representing compensation-related acquisitions of options to buy Common Shares, not open-market trading activity in ProMIS Neurosciences stock.

How many ProMIS Neurosciences options does William Wyman hold after these grants?

After these awards, one option position shows 11,000 derivative securities and another shows 5,500, as reported following each transaction. These reflect the option amounts tied to the new grants, each linked to the right to acquire an equal number of Common Shares upon exercise.